← SynDRA
BAY-1125976
SynDRA canonical compound SYN0040215 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | AKT1 | AKT2 |
|---|
| Mechanism of action | AKT inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- AKT1 INHIBITOR
- Serine/threonine-protein kinase AKT inhibitor
- AKT2 INHIBITOR
- Serine/threonine-protein kinase AKT2 inhibitor
- AKT1 NEGATIVE ALLOSTERIC MODULATOR
- AKT2 NEGATIVE ALLOSTERIC MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CLK1
- FLT1
- AKT3
- CHRM1
- MKNK2
- ADRA1A
- HTR2C
- HTR3A
- HTR5A
- HTR6
- HTR7
- MBD4
- MUTYH
- NEIL2
- OPRD1
- OGG1
- HTR2A
- OPRK1
- OPRM1
- SIGMAR1
- SLC6A2
- SLC6A3
- SLC6A4
- SMUG1
- TDG
- TMEM97
- HTR2B
- HTR1A
- HTR1D
- CHRM4
- ADRA1D
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB1
- ADRB2
- ADRB3
- CHRM2
- CHRM3
- CHRM5
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- BAY 1125976
- BAY1125976
- UNII-ZL7A1UM87X
- Example 5 [WO2012136776A1]
- Example 5 (WO2012136776A1)
- RefChem:116721
- AKT 1/2 Inhibitor BAY1125976
- BAY 1125976 [WHO-DD]
- ZL7A1UM87X
- MFCD30481340
- orb1299928
- SCHEMBL12986078
- US9604989, Example 5
- C23H21N5O
- GTPL10908
- JBGYKRAZYDNCNV-UHFFFAOYSA-N
- BDBM312517
- GLXC-25793
- CGC60802
- EX-A3015
- BAY112576
- NSC793324
- s8500
- AKOS030627404
- BAY-112576
- CS-6212
- NSC-793324
- SB19771
- BAY1125976?
- NCGC00509934-02
- AC-33646
- MS-26301
- HY-100018
- T7315
- F85509
Look up BAY-1125976 in the interactive SynDRA portal →